Opinion

Video

Updates in Approaches for Prostate Cancer Biopsy and Diagnosis

Author(s):

Amir H. Lebastchi, MD

Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      1 expert in this video
      Using Ultrasensitive PSA Assays in Routine Practice
      1 expert in this video
      Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Related Content
      Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
      June 4th 2025

      ARANOTE: Darolutamide improves HRQoL in mHSPC

      Benjamin P. Saylor
      Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      FDA approves darolutamide in metastatic castration-sensitive prostate cancer
      June 3rd 2025

      FDA approves darolutamide in metastatic castration-sensitive prostate cancer

      Hannah Clarke
      The approval is supported by data from the pivotal phase 3 ARANOTE trial.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Alicia Morgans, MD, MPH
      June 3rd 2025

      Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

      Benjamin P. Saylor
      “As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
      Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
      June 2nd 2025

      Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC

      Hannah Clarke
      Data also showed a positive trend in overall survival.
      © 2025 MJH Life Sciences

      All rights reserved.